HIV Business Growth
HIV sales increased by 6% year over year, driven by higher average realized price and demand. Biktarvy sales were up 7% year over year, highlighting strong demand-led volume growth.
Livedelzi Market Entry Success
Livedelzi continues its strong launch momentum, with $40 million in sales in its second full quarter, capturing about a third of the market in its category.
Trodelvy Phase III Success
Trodelvy plus pembrolizumab demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the phase III ASCENT-04 trial for first-line PD-L1 positive metastatic triple-negative breast cancer.
Positive Operating Margins
The company reported strong operating margin and earnings per share, reflecting effective expense management.
Strong Cell Therapy Outlook
Anetocel remains on track to potentially launch in 2026 for relapsed refractory multiple myeloma, with promising clinical profiles and manufacturing capabilities.
Improvements in Liver Disease Sales
Sales increased by 3% year over year, driven by demand across PBC, HBV, and HDV, despite lower average realized prices for HCV products in the US.